TNFRSF17 and plasma cell myeloma: We note that three additional BsAbs: anti-CD3/CD269, teclistamab (138), and elranatamab (139); and anti-CD3/CD20, mosunetuzumab (147) are approved for the treatment of myeloma and non-Hodgkin’s lymphoma, respectively, by the US Food and Drug Administration (FDA), and are under review by NICE.